Patent & IP news for October 6, 2013

Coming soon: International Patent Litigation 2013 from ipkitten.blogspot.com

If the dust swirls too much,
even patent specs won't help  When it comes to patent litigation, there is no metaphor more apt than that of dust. When frantic activity ceases, whether in the ...

Share via E–mail | Twitter | Facebook

Of Purple Haze and Scrabble Plays: appeal court says "no" to fuzzy trade mark descriptions from ipkitten.blogspot.com

Before anyone else emails the IPKat to let him know, he can tell you that he is fully aware of the two big trade mark rulings from the Court of Appeal for England and Wales ...

Share via E–mail | Twitter | Facebook

International Patent Litigation 2013 event: discount available to PatLit readers from patlit.blogspot.com

Conferencing in comfort? "International Patent Litigation 2013" is the title of the fifth successive annual conference on the topic which is being organised by IBC Legal Conferences.  The conference takes place on 10 and 11 ...

Share via E–mail | Twitter | Facebook

Where two is no worse than one: Irish allow joint trade mark oppositions by unrelated parties from ipkitten.blogspot.com

Still playing catch-up ... Marie Claire Netherlands B.V. v Marie Claire S.A. & Brandwell (IRL) Ltd, a 10 July decision of Dermot Doyle, acting for the Controller of the Irish Patents Office, caught this Kat ...

Share via E–mail | Twitter | Facebook

Conference & CLE Calendar from www.patentdocs.org

October 9, 2013 - Biosimilars: Navigating FDA's Evolving Approval Pathway, Protecting Patents and Trade Secrets (Strafford) - 1:00 to 2:30 pm (EDT) October 10, 2013 - Recent Judicial Decisions Impacting Technology Licensing (McDonnell Boehnen Hulbert ...

Share via E–mail | Twitter | Facebook

Court Report from www.patentdocs.org

By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Forest Laboratories Inc. et al. v. First Time US Generics LLC 1:13-cv-01642; filed October 2 ...

Share via E–mail | Twitter | Facebook